Wall Street opened a new week seeking footing after a broad index selloff left all four major benchmarks lower, with the CBOE Volatility Index remaining elevated. The Nasdaq Composite posted the steepest weekly decline among the major averages, while the S&P 500, Dow Jones Industrial Average and Russell 2000 also finished in the red.
Weekly Losses Across Major Benchmarks
The Dow Jones Industrial Average fell 0.94% to 51,285.73, while the S&P 500 dropped 2.68% to 7,376.86. The Nasdaq Composite lost 3.37% to 24,579.43, and the Russell 2000 slid 2.05% to 2,754.11. The Nasdaq’s high for the week was 26,048.83, compared with a low of 24,262.14, highlighting the wide range traders navigated.
The CBOE Volatility Index settled at 23.5, up 2.35 points for the week even after easing 2.14 points on the day. The gauge’s elevated level suggests that traders are still weighing whether recent lows mark a floor or merely a pause before further declines.
Technical Gauges Point to Oversold Conditions
The S&P 500 carries a 14-day relative strength index of 35.1, and the Nasdaq sits at 33.9, both pointing toward oversold territory. The Dow’s RSI of 43.2 and the Russell’s 43.0 suggest somewhat less stress. Key support for the S&P 500 sits at 7,333.68, just below Friday’s close, with the 200-day simple moving average at 7,313.92 as a deeper backstop. The Nasdaq’s nearest support is 24,491.83.
Commodities and Treasury Yields Diverge
In commodities, gold climbed 3.70% on the week to $4,116.60 per ounce, and silver gained 3.86% to $52.68. WTI crude tumbled 8.48% to $88.28 per barrel, while natural gas rose 5.36% to $3.01 per MMBtu. The US 10-year Treasury yield eased 7 basis points on the week to 4.86%, even as it ticked up 2 basis points in the latest session.
Corporate Developments in Focus
Enbridge Inc. reported third-quarter GAAP earnings attributable to common shareholders of $1.3 billion, or $0.59 per common share, compared with $0.7 billion, or $0.30 per common share, in 2025. Adjusted earnings were $1.1 billion, or $0.49 per common share, versus $1.0 billion, or $0.46 per common share, a year earlier. Adjusted EBITDA was $4.4 billion compared with $4.3 billion in 2025. The company reaffirmed its 2026 full-year financial guidance and medium-term outlook, placed more than $3 billion of gas transmission projects into service during the quarter, and announced the US$2.6 billion acquisition of Tallgrass Energy LP’s crude oil business. Enbridge also closed the US$0.6 billion acquisition of Salt Creek Midstream’s crude oil gathering business. President and CEO Greg Ebel said the secured growth backlog stands at $38 billion.
Amgen reported third-quarter total revenues of $10.4 billion, up 8% from the third quarter of 2025, with product sales also growing 8%. Seventeen products delivered at least double-digit sales growth, and seventeen products are annualizing at more than $1 billion based on third-quarter sales. GAAP earnings per share increased 19% to $7.08 from $5.93, while GAAP operating margin rose 9.9 percentage points to 37.5%. Non-GAAP EPS increased 14% to $6.45, and the company generated $3.7 billion of free cash flow in the quarter, compared with $4.2 billion a year earlier. Chairman and CEO Robert A. Bradway said the company delivered another strong quarter. UPLIZNA sales increased 191% year-over-year to $451 million, while Prolia sales decreased 45% to $632 million amid biosimilar competition.
Thomson Reuters reported third-quarter total company revenues up 10%, with organic revenues also up 10% in total and 10% for its Big 3 segments. Adjusted EBITDA rose 10% to $651 million, though adjusted EBITDA margin dipped to 35.5% from 35.8% a year earlier. The company closed the sale of a 51% stake in its Global Print business to capital accounts advised by KKR for gross proceeds of approximately $500 million on October 1, 2026, and updated its full-year 2026 outlook to exclude that business, now expecting total revenue growth of approximately 9.5%. Diluted EPS decreased to $0.78 from $0.94, while adjusted EPS increased to $0.81 from $0.71. President and CEO Steve Hasker said revenue growth and margins came in ahead of prior expectations.
Sun Life Financial Inc. reported underlying net income of $1,146 million, up $99 million or 9% from the third quarter of 2025, with underlying EPS of $2.05, up 10%. Reported net income of $785 million decreased $321 million or 29% from a year earlier, and reported EPS of $1.40 fell 29%. Underlying ROE was 19.0% compared with 18.3% a year earlier, while reported ROE was 13.0% versus 19.3%. Assets under management reached $1,676 billion, up $53 billion or 3% from the third quarter of 2025, and the company increased its common share dividend from $0.96 to $1.00 per share. President and CEO Kevin Strain said the company delivered a solid third quarter with growth across Canada, Asia, U.S. stop loss, and GreenOak.
Eli Lilly and Company and Hims & Hers Health announced an agreement to expand access to Zepbound and Foundayo through the Hims & Hers platform. Eligible patients receiving a prescription from a licensed provider will be able to access self-pay prices starting at $149 per month for Foundayo and $299 per month for Zepbound without leaving the platform. Ilya Yuffa, Executive Vice President and President of Lilly USA and Global Customer Capabilities, said millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed. As part of the agreement, both companies committed to protecting independent clinical decision-making so providers continue to prescribe what they determine is right for each patient. The companies also noted Hims & Hers has never offered compounded copies of Lilly’s GLP-1 medicines and has committed not to do so in the future.
